Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03687606
Other study ID # TJ-IRB20180906
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date October 18, 2018
Est. completion date October 1, 2025

Study information

Verified date April 2020
Source Tongji Hospital
Contact Hao Xu, M.D
Phone +86-15872427301
Email haoxutjmu@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of long term use of hCG alone or hCG plus hMG in the treatment of male patients with isolated hypogonadotropic hypogonadism (IHH). One third of the participants will receive hCG treatment alone and the other third of the participants will receive hCG treatment alone for six months, then the hMG will be added. And the last third of the participants will receive hCG and hMG treatment since the beginning of the treatment.


Description:

The efficacy of hCG alone or hCG plus hMG in the treatment of male IHH patients was reported in some studies. However, these studies were mostly non-randomized controlled studies with small size of samples and short follow-up time. There was also no reported study which aimed to compare the efficacy and safety of long term use of hCG or hCG plus hMG in the treatment of male patients with IHH. So the difference in the efficacy and safety between long term use of hCG alone and hCG plus hMG in the treatment of IHH is unknown. In different reported studies, the hCG plus hMG treatment had two regimens: using hCG alone for six month, then hMG was added and using hCG plus hMG since the beginning of the treatment. The difference in the efficacy and safety between the above two regimes is also unknown.


Recruitment information / eligibility

Status Recruiting
Enrollment 210
Est. completion date October 1, 2025
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Age = 18, = 45 years old;

2. Adolescent dysplasia or loss of puberty: Genital Tanner score ? 5, pubic hair Tanner score ? 5;

3. Serum FSH and LH levels are low or in normal low value, testosterone was lower than normal range (1.75ng / ml, the lower limit of the normal blood testosterone reference range of Tongji Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology);

4. With or without olfactory loss/reduction;

5. Other pituitary hormone levels are normal;

6. Head MRI examination is normal;

7. Fertility is desired currently or will be desired in the future;

8. Understand and sign the informed consent form.

Exclusion Criteria:

1. Primary hypogonadism;

2. Acquired hypogonadotrophic hypogonadism;

3. A history of treatment with pulsed GnRH, hCG and FSH related hormones;

4. Receive testosterone replacement therapy for more than 6 months;

5. History of cryptorchidism or cryptorchidism;

6. The sperm density before treatment =1×10^6/ml;

7. Moderate or severe liver and kidney dysfunction (ALT>120IU/L, AST>80IU/L, CR>115µmol/L);

8. The karyotype is 45,X or 47,XXY and 48, XXXY and other abnormal karyotypes;

9. True hermaphroditism and pseudohermaphroditism;

10. Sex hormone abnormalities caused by adrenal lesions;

11. Hypogonadism secondary to other systemic diseases;

12. Abnormal secretion of hormones caused by brain lesions (such as pituitary tumors);

13. There are other hormone abnormalities in the pituitary;

14. There are contraindications for the treatment with hCG or hMG.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Human Chorionic Gonadotropin
White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
human menopausal gonadotropin
White freeze-dried cake or powder with specification of 75IU.

Locations

Country Name City State
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Tongji Hospital

Country where clinical trial is conducted

China, 

References & Publications (2)

Matsumoto AM, Snyder PJ, Bhasin S, Martin K, Weber T, Winters S, Spratt D, Brentzel J, O'Dea L. Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f): long-term treatment in azoospermic men with hypogonadotropic hypogonadism. Fertil Steril. 2009 Sep;92(3):979-90. doi: 10.1016/j.fertnstert.2008.07.1742. Epub 2008 Oct 18. — View Citation

Zacharin M, Sabin MA, Nair VV, Dabadghao P. Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis. Fertil Steril. 2012 Oct;98(4):836-42. doi: 10.1016/j.fertnstert.2012.06.022. Epub 2012 Jul 3. Erratum in: Fertil Steril. 2013 May;99(6):1798. Dagabdhao, Preeti [corrected to Dabadghao, Preeti]. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Height Height will be measured at every visit. 3 months.
Other Weight Weight will be measured at every visit. 3 months.
Other Feeling of inferiority scale score Feeling of inferiority scale scores will be obtained using feeling of inferiority scale. 3 months.
Primary Sperm density Sperm density will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits. 6 months.
Secondary Semen volume Sperm volume will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits. 6 months.
Secondary Sperm activity Sperm activity will be obtained in the semen sample analysis using the World Health Organization (WHO) normal values based on the WHO 2010 reference limits. 6 months.
Secondary The time for sperm to appear during treatment The time for the sperm firstly appeared in the semen will be recorded. 6 months.
Secondary Serum testosterone levels The serum testosterone levels will be tested in every visit. 3 months.
Secondary Testicular volume Testicular volume will be measured using a Prader orchidometer. 3 months.
Secondary Penis length Penis length will be measured from the pubic symphysis to glans using a vernier caliper. 3 months.
Secondary Pubic hair Pubic hair will be evaluated according to Tanner pubertal stages. 3 months.
Secondary Genitalia Genitalia will be evaluated according to Tanner pubertal stages. 3 months.
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A